drugset / Trial / NCT00738322

To Study Safety, Tolerability and Pharmacokinetics of AZD1305 in Healthy Male Japanese Subjects

NCT00738322

Phase 1 Completed 36 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose is to study the safety of AZD1305, how AZD1305 is tolerated and how the medication is metabolised by the body ( how it is taken up into the body, distributed around the body and disappears from the body) in healthy Japanese males.

Timeline

Start
2008-07
Primary completion
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD1305 Small molecule Intravenous

Indications

No indication recorded.